Key Milestones in Apotex's Ruxolitinib ANDA Review
Apotex filed its Abbreviated New Drug Application (ANDA) for a generic version of Incyte's Jakafi (ruxolitinib) tablets, targeting Paragraph IV challenges to multiple Orange Book patents. The FDA review process unfolded over several years amid patent litigation.
- December 21, 2018: Apotex submits ANDA 210880 to FDA, seeking approval for 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths.[1][2]
- May 2021: FDA issues a Complete Response Letter (CRL) due to manufacturing inspection issues at Apotex's facilities.[1]
- October 2022: FDA tentatively approves the ANDA, pending resolution of patent exclusivity and litigation.[1][3]
- Patent Litigation Filing: Incyte sues Apotex in December 2018 under Hatch-Waxman; case consolidates in Delaware federal court (Incyte Corp. v. Apotex Inc., No. 1:18-cv-02022).[2][4]
- October 31, 2023: District court rules most asserted claims invalid or not infringed; Incyte appeals to Federal Circuit.[4][5]
- February 8, 2024: FDA grants final approval to Apotex's ANDA 210880, effective immediately, allowing market entry after 30-month stay expires (June 22, 2024).[1][3]
When Could Apotex Launch Its Generic?
Apotex received final FDA approval on February 8, 2024, but the 30-month automatic stay from the 2018 litigation delayed launch until June 22, 2024. Incyte's ongoing appeal could lead to an injunction, though Apotex launched at-risk on July 1, 2024.[3][5][6]
Why Did Review Take Over 5 Years?
Standard ANDA reviews average 30-36 months, but Apotex's faced delays from a 2021 CRL on cGMP compliance, plus patent disputes extending the stay. Tentative approval in 2022 signaled resolution of technical issues.[1][2]
Status of Related Patents and Exclusivity
| Patent/Aspect | Status | Expiration |
|---------------|---------|------------|
| Core composition patents (e.g., U.S. 7,598,257) | Invalidated or non-infringed per 2023 ruling[4] | Varies; some 2027-2029 |
| Pediatric exclusivity | Expired January 2024[7] | N/A |
| 180-day generic exclusivity | Held by Apotex (first filer); shared if others qualify[3] | Starts post-stay |
Check DrugPatentWatch.com for full Orange Book listings and litigation updates: Ruxolitinib Patents.[7]
Competitors in Ruxolitinib Generics
Apotex leads as first Para IV filer, but Sandoz, Lupin, and others have tentative approvals or ongoing suits. No other generics launched by mid-2024.[3][6]
Sources
[1]: FDA ANDA Approval Letter for Apotex Ruxolitinib
[2]: Incyte v. Apotex Complaint
[3]: FDA Tentative-to-Final Approval Notice
[4]: Delaware Court Ruling (Oct 2023)
[5]: Federal Circuit Appeal Docket
[6]: Apotex Launch Press Release
[7]: DrugPatentWatch.com - Jakafi